A Phase 2 interventional study of Ruxolitinib and Capecitabine in Pancreatic Cancer, Colorectal Cancer (CRC) and Breast Cancer, sponsored by Incyte Corporation. Active, not recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies testing capecitabine in Pancreatic Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. Capecitabine · Pancreatic Neoplasms.
Among the 81 studies testing capecitabine in Pancreatic Neoplasms, this one is the 69th largest by enrollment of the 79 interventional ones that give a count, is one of 4 that started in 2016, is one of 39 in phase 2, and was the 69th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →4 of the 81 studies testing capecitabine in Pancreatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Henry Ford Health System · Sites in United States
Ages 18+
EBG MedAustron GmbH · Sites in Austria
Ages 18+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 20+
Proton Collaborative Group · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 51 · Phase 3 7
First in 1999; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 40 across the 79 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 81 have an industry lead sponsor. The 10 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
10 studies in Pancreatic Neoplasms by Incyte Corporation: 1 open now, 2 under way, 1 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 10 studies in Pancreatic Neoplasms by Incyte Corporation, this one is the 9th largest by enrollment, is one of 3 that started in 2016, is one of 2 in phase 2, and was the 9th registered.
Incyte Corporation’s Pancreatic Neoplasms studies by the year they started, since 2011.
4 of the studies testing capecitabine in Pancreatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT04894643EBG MedAustron GmbHPreoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | 2026-12-31 |
| NCT03523312Memorial Sloan Kettering Cancer CenterUse of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer | 2027-04 |
| NCT02955940Incyte CorporationAn Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 81 studies testing capecitabine in Pancreatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Incyte Corporation’s 10 in Pancreatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated.
This study will also provide another mechanism for reporting adverse events related to study drug safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
Drug: Ruxolitinib
Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
Drug: Ruxolitinib · Drug: Capecitabine · Drug: Regorafenib
Capecitabine and Regorafenib at the same dose provided in the parent study at the time of the rollover.
Drug: Capecitabine · Drug: Regorafenib
5 mg BID
Also known as: INCB018424, Jakafi®
Capecitabine at the same dose provided in the parent study at the time of the rollover.
Also known as: Xeloda®
Regorafenib at the same dose provided in the parent study at the time of the rollover.
Also known as: Stivarga®
Frequency and types of adverse events and serious adverse events
Subjects will be treated until disease progression or discontinuation criteria are met.
Time frame: Maximum duration of every 2 months (maximum duration of 1 month for subjects receiving regorafenib) from enrollment through 30-37 days after end of treatment up to 24 months.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Started Nov 2016 (actual). Primary completion is estimated for Sep 2027, 130 months after the start.
Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 130 months is above that.
Counting every sponsor, half of 394 studies reached it within 57 months; a quarter within 35 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ruxolitinib · Capecitabine · Regorafenib